• U.S. FDA approved subcutaneous induction dosing of AbbVie's Skyrizi for adults with moderately to severely active Crohn's disease.
• The regimen allows patients to begin treatment at home using an on-body injector, then continue maintenance dosing every eight weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610231533PR_NEWS_USPR_____CG77917) on October 23, 2026, and is solely responsible for the information contained therein.